Today APEX Ventures has announced launching its second fund, focusing on digital health startups. The fund will back seed stage deep-tech companies with defendable IP. APEX Ventures invests in exceptional talented teams who are committed to improving patient outcomes and lives, and firmly believes that diversity and inclusion are key to building a strong community of entrepreneurs.
The announcement follows a successful few weeks for APEX Ventures, which saw an exit for portfolio company ‘Lendflo’ and the completion of four new investments in the areas of digital pathology, radiology and neurology.
The fund will be headed by partner Gordon Euller, a qualified doctor and radiologist who has previously worked at AKH, Vienna’s General Hospital, as well as at McKinsey in London. “COVID-19 demonstrates to us worldwide how vulnerable our medical systems and processes are, particularly regarding capacity. These issues can only be solved by new innovative technologies as well as generous and wise investments in this asset category,” said Euller.
Founded in 2017, to date most of APEX Ventures’ investments have been made in the DACH region, through its Austrian base. With APEX Digital Health, the focus area will expand from DACH-based companies, to those based in the rest of Europe, Israel and the US.
Venture partner Kelly Klein has recently joined the Fund to head up the firm’s activities in Israel. “Digital health is really prospering in Israel,” says Klein, “and one way this is done is by leveraging its medical data; Israel has 25 years of data and 90% of this is digitalised. One of the most important things once an Israeli startup gets funding is to internationalise it, and APEX can help to expand in the US, Europe and Asia.”
In addition, APEX Ventures will shortly issue a call (along with the Herman Hauser Investment Group) for the best European startups in the strategic areas of In-silico trials and AI supported healthcare data marketplaces.